Orphazyme A/S

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Orphazyme A/S (NASDAQ: ORPH): (1) pursuant and/or traceable to Orphazyme’s September 29, 2020 initial public offering (the “IPO” or “Offering”); and/or (2) between September 29, 2020 and June 18, 2021, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 7, 2021.

If you purchased Orphazyme securities and would like to join the action, please click “Join This Class Action.”

If you purchased Orphazyme securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit,  Offering documents and defendants during the Class Period made false and/or misleading statements and/or failed to disclose that:

  • arimoclomol was not as effective in treating Inclusion Body Myositis (“IBM”) as defendants had represented;
  • arimoclomol was not as effective in treating Amyotrophic Lateral Sclerosis (“ALS”) as defendants had represented;
  • the arimoclomol new drug application (“NDA”) for Niemann-Pick disease type C (“NPC”) was incomplete and/or required additional evidence and data to support the benefit-risk assessment of that NDA;
  • as a result, the U.S. Food and Drug Administration (“FDA”) was unlikely to approve the arimoclomol NDA for NPC in its present form;
  • the Company’s overall business prospects, as well as arimoclomol’s commercial prospects, were significantly overstated; and
  • as a result, the Company’s public statements were materially false and misleading at all relevant times.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: Orphazyme A/S
股票代号: ORPH
集体诉讼期: Pursuant and/or traceable to Orphazyme’s September 29, 2020 IPO and/or (2) between September 29, 2020 and June 18, 2021
法院: United States District Court for the Northern District of Illinois


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。